The N-myc gene was originally identified in human neuroblastoma cell lines and was grouped as a protooncogene because ofits partial homology to the protooncogene c-myc.'2 Close correlation between genomic amplification of the N-myc gene in neuroblastomas and the stage and aggressiveness of the tumours was first reported by Brodeur et al3 and Seeger et al. 4 The key role of N-myc gene amplification in determining the biological behaviour of neuroblastomas has also been given further support.56 The enhanced expression of N-myc has also been detected in relation to malignant progression, using Northern blot analysis or in situ hybridisation techniques."8 Recently, antibodies against genetically engineered N-myc gene products were prepared>" and these tools paved the way for retrospective immunohistochemical studies on the N-myc gene product.
We used immunohistochemical techniques to evaluate distribution of the N-myc gene product on paraffin wax sections of neuroblastomas and compared our findings with the number of N-myc gene copies and how this affected prediction of the prognosis of the patients.
Material and metbods
Between 1979 and 1986 13 cases ofneuroblastoma and five of ganglioneuroblastoma (two composite, two Accepted for publication 21 July 1988 well differentiated, one poorly differentiated) were selected for study. In all tumours the number ofcopies of N-myc gene had been determined by Southern blot analysis, using radiolabelled N-myc (NB-19-21), the details of which have been reported elsewhere.56
Five micron sections of 10% formalin fixed, paraffin wax embedded material were mounted on slides coated with poly(L-lysine) for immunohistochemical study. After the tissue sections had been deparaffinised and the endogenous peroxidase activity blocked by using a short 10 minute oxidation procedure in 0 5% periodic acid, followed by treatment with a freshly prepared 0-02% sodium borohydrate for 30 minutes, the avidin-biotin peroxidase complex (ABC) method of Hsu et al 2 was used to determine localisation of the N-myc gene product. The slides were immersed in 10% normal goat serum for 30 minutes to eliminate the non-specific binding of immunoglobulins and then incubated overnight at 4°C with the affinity purified anti-human N-myc gene product rabbit IgG (MBL, Nagoya, Japan) diluted 1/10. The antibody was produced against the genetically engineered human N-myc gene product." After a buffer wash 50 pg/ml of the biotinylated anti-rabbit goat immunoglobulin was applied for 30 minutes. The avidin-biotin peroxidase complex (Vector, Burlingame, California, USA) was applied for an additional 60 minutes at room temperature. The site of localisation of the peroxidase label was then identified by formation of a brown reaction product, using hydrogen peroxidase and diaminobenzidine. These sections were lightly counterstained with methyl green. N-myc gene product expression in neuroblastoma 
Discussion
In 1986 Ikegaki et al identified and characterised the N-myc gene product in human neuroblastoma cells, using monoclonal antibodies with defined specificities. These were prepared against a bacterially expressed fusion protein containing a portion of the N-myc sequence.'" The relative level of the polypeptides was roughly proportional to the level of N-myc transcripts present in a panel of neuroblastoma cell lines. We applied an affinity purified rabbit antibody against the genetically engineered human N-myc oncogene product prepared by Shimatake et al " to paraffin wax sections. Those authors reported that: (i) Western blot analysis showed the presence of the N-myc protein (63 kd) in the nuclear fraction of the neuroblastoma cells examined; (ii) immunohistochemically, the N-myc protein was distributed in the nuclei ofneuroblastoma cells obtained from various culture cell lines, a xenograft, and a surgical specimen; (iii) the anti-N-myc antibody did not react with cells producing c-myc in the enzyme linked immunosorbent assay (ELISA), or in immunohistochemical tests.
In nine of our 18 tumours, there were tumour cells positive for the N-myc gene product. The immunoreaction products were recognised only in the nuclei of neuroblastoma cells, with virtually no staining in the cytoplasm of these cells or normal ganglion cells, nephrons, and vascular or other stromal elements. Almost all the positive cells seemed to be primitive neuroblasts and were not observed among neuroblastic cells showing differentiation, even in the same tumour. A close relation of N-myc oncogene positivity to undifferentiated phenotypes in neuroblastoma cells is compatible with the finding that in situ hybridisation to sections of neuroblastomas showed a high expression of N-myc, predominantly in the undifferentiated neuroblasts.78 The expression of N-myc was found to be greatly decreased before morphological evidence of differentiation when primitive human neuroblastoma cell lines were differentiated in vitro by the addition of retinoic acid.'4" The N-myc oncogene may therefore have an important role in the oncogenicity, proliferating ability, and regulation of cell differentiation of neuroblastomas.
Increased production of N-myc protein seems to correlate closely with N-myc gene amplification and a poor prognosis. Nine of the 11 neuroblastic tumours with the amplified N-myc gene copies contained Nmyc protein positive tumour cells, while none of the seven non-amplified cases showed immunostaining for N-myc. Because the N-myc gene product has been reported to have a short half life (30-40 minutes),'0 the negativity for the N-myc protein in the two cases with amplified N-myc gene copies may have been the result of a loss of intranuclear N-myc protein by the prolonged lapse of time until fixation or delayed permeation of fixatives. Even though there may be some loss of the antigen, patients with an N-myc immunoreactive neuroblastoma had a significantly poorer prognosis than did those with a neuroblastoma negative for N-myc protein. These results suggest that amplification and consequent increased transcripts of the Nmyc oncogene may be related to the aggressiveness of neuroblastomas. Immunohistochemical examination for the N-myc gene product in neuroblastomas is thus useful for predicting the prognosis of these patients.
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